JA Sparano

Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen

JA Sparano, Wiernik Ph, Margery Strack et al. · Blood · 1993 · 77 citations · Full text

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

RS Finn, Carmelo Bengala, Nuhad Ibrahim et al. · Cancer Research · 2009 · 70 citations

Breast Oncology, Cancer Management, Pathology +17

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Lori J. Goldstein, Anne O’Neill, JA Sparano et al. · Journal of Clinical Oncology · 2005 · 67 citations

Breast Oncology, Negative Breast Cancer, Pathology +22

Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088

E. Mayer, Jean‐François Baurain, JA Sparano et al. · Journal of Clinical Oncology · 2009 · 26 citations

Advanced Her2/neu, Breast Oncology, Er/pr-positive Breast Cancer +12

A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer.

Edith A. Perez, Xavier Pivot, Eduard Vrdoljak et al. · Cancer Research · 2009 · 21 citations

Ixa-induced Pn, Neuropathic Pain, Pharmacotherapy +20